These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Gattei V; Bulian P; Del Principe MI; Zucchetto A; Maurillo L; Buccisano F; Bomben R; Dal-Bo M; Luciano F; Rossi FM; Degan M; Amadori S; Del Poeta G Blood; 2008 Jan; 111(2):865-73. PubMed ID: 17959854 [TBL] [Abstract][Full Text] [Related]
106. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Haferlach C; Dicker F; Schnittger S; Kern W; Haferlach T Leukemia; 2007 Dec; 21(12):2442-51. PubMed ID: 17805327 [TBL] [Abstract][Full Text] [Related]
107. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Pfeifer D; Pantic M; Skatulla I; Rawluk J; Kreutz C; Martens UM; Fisch P; Timmer J; Veelken H Blood; 2007 Feb; 109(3):1202-10. PubMed ID: 17053054 [TBL] [Abstract][Full Text] [Related]
108. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Schwaenen C; Nessling M; Wessendorf S; Salvi T; Wrobel G; Radlwimmer B; Kestler HA; Haslinger C; Stilgenbauer S; Döhner H; Bentz M; Lichter P Proc Natl Acad Sci U S A; 2004 Jan; 101(4):1039-44. PubMed ID: 14730057 [TBL] [Abstract][Full Text] [Related]
109. Genomic aberrations and survival in chronic lymphocytic leukemia. Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261 [TBL] [Abstract][Full Text] [Related]
110. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Cheson BD; Bennett JM; Grever M; Kay N; Keating MJ; O'Brien S; Rai KR Blood; 1996 Jun; 87(12):4990-7. PubMed ID: 8652811 [No Abstract] [Full Text] [Related]
111. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Matutes E; Owusu-Ankomah K; Morilla R; Garcia Marco J; Houlihan A; Que TH; Catovsky D Leukemia; 1994 Oct; 8(10):1640-5. PubMed ID: 7523797 [TBL] [Abstract][Full Text] [Related]
112. MYCN oncoprotein targets and their therapeutic potential. Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925 [TBL] [Abstract][Full Text] [Related]
113. Genes and chromosomes in chronic B-cell leukemia. Crossen PE Cancer Genet Cytogenet; 1997 Mar; 94(1):44-51. PubMed ID: 9078290 [TBL] [Abstract][Full Text] [Related]
114. Regulation of the turnover of mRNAs encoding cellular oncoproteins. Saini KS; Summerhayes IC Biochem Cell Biol; 1991 Jul; 69(7):415-7. PubMed ID: 1838927 [No Abstract] [Full Text] [Related]
115. Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. Deambrogi C; De Paoli L; Fangazio M; Cresta S; Rasi S; Spina V; Gattei V; Gaidano G; Rossi D Am J Hematol; 2010 Jul; 85(7):541-4. PubMed ID: 20575024 [No Abstract] [Full Text] [Related]
117. The MYCN oncoprotein as a drug development target. Lu X; Pearson A; Lunec J Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971 [TBL] [Abstract][Full Text] [Related]